title: Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study.
abstract: A prospective study was performed to establish whether infection with specific hepatitis C virus (HCV) genotypes was associated with an increased risk of development of hepatocellular carcinoma (HCC) in cirrhosis. A cohort of 163 consecutive hepatitis C virus antibody (anti-HCV)-positive cirrhotic patients was prospectively evaluated for the development of HCC at 6-month intervals by ultrasound (US) scan and alpha-fetoprotein (AFP) concentration. HCV genotypes were determined according to Okamoto. Risk factors associated with cancer development were analyzed by univariate and multivariate statistics. At enrollment, 101 patients (62%) were infected with type 1b, 48 (29.5%) were infected with type 2a/c, 2 (1.2%) were infected with type 3a, 1 (0.6%) was infected with type 1a, 3 (1.8%) had a mixed-type infection, and, in 8 patients (4.9%), genotype could not be assigned. After a 5- to 7-year follow-up (median, 68 months), HCC developed in 22 of the patients, 19 infected with type 1b and 3 with type 2a/c (P < .005). Moreover, HCC developed more frequently in males (P < .01), patients with excessive alcohol intake (P < .01), those over 60 years of age (P < .02), and in patients who did not receive interferon treatment (P < .02). Multivariate analysis showed that type 1b was the most important risk factor associated with tumor development (odds ratio 6.14, 1.77-21.37 95% confidence interval). Other independent risk factors were older age and male sex. Cirrhotic patients infected with HCV type 1b carry a significantly higher risk of developing HCC than patients infected by other HCV types. The latter may require a less intensive clinical surveillance for the early detection of neoplasia.
authors.affiliation: Divisione di Medicina Generale III, Cattedra di Medicina Interna, Istituto di Scienze Biomediche San Paolo, Universita di Milano, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Bruno
authors.forename: E
authors.initials: E
authors.lastname: Silini
authors.forename: A
authors.initials: A
authors.lastname: Crosignani
authors.forename: F
authors.initials: F
authors.lastname: Borzio
authors.forename: G
authors.initials: G
authors.lastname: Leandro
authors.forename: F
authors.initials: F
authors.lastname: Bono
authors.forename: M
authors.initials: M
authors.lastname: Asti
authors.forename: S
authors.initials: S
authors.lastname: Rossi
authors.forename: A
authors.initials: A
authors.lastname: Larghi
authors.forename: A
authors.initials: A
authors.lastname: Cerino
authors.forename: M
authors.initials: M
authors.lastname: Podda
authors.forename: M U
authors.initials: MU
authors.lastname: Mondelli
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000188:drug therapy / Q000821:virology*; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D006526:Hepatitis C / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000821:virology*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000097:blood / Q000188:drug therapy / Q000821:virology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011446:Prospective Studies; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D000998:Antiviral Agents; D014408:Biomarkers, Tumor; D007372:Interferons